CA2154896A1 - Agents immunoreactifs utilisant des heterodimeres - Google Patents

Agents immunoreactifs utilisant des heterodimeres

Info

Publication number
CA2154896A1
CA2154896A1 CA002154896A CA2154896A CA2154896A1 CA 2154896 A1 CA2154896 A1 CA 2154896A1 CA 002154896 A CA002154896 A CA 002154896A CA 2154896 A CA2154896 A CA 2154896A CA 2154896 A1 CA2154896 A1 CA 2154896A1
Authority
CA
Canada
Prior art keywords
group
reagent
residue
mrp8
subunit proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002154896A
Other languages
English (en)
Inventor
Robert Allen Snow
Christopher Douglas Valiant Black
Clyde William Shearman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2154896A1 publication Critical patent/CA2154896A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002154896A 1993-01-28 1994-01-26 Agents immunoreactifs utilisant des heterodimeres Abandoned CA2154896A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1054493A 1993-01-28 1993-01-28
US010544 1993-01-28
PCT/US1994/000965 WO1994016741A1 (fr) 1993-01-28 1994-01-26 Reactants immunoreactifs utilisant des heterodimeres

Publications (1)

Publication Number Publication Date
CA2154896A1 true CA2154896A1 (fr) 1994-08-04

Family

ID=21746245

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002154896A Abandoned CA2154896A1 (fr) 1993-01-28 1994-01-26 Agents immunoreactifs utilisant des heterodimeres

Country Status (5)

Country Link
EP (1) EP0681484A1 (fr)
JP (1) JPH08509955A (fr)
AU (1) AU6128694A (fr)
CA (1) CA2154896A1 (fr)
WO (1) WO1994016741A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507233A (ja) * 1996-03-13 2000-06-13 デュポン ファーマシューティカルズ カンパニー 新規の三元複合体放射性薬剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand

Also Published As

Publication number Publication date
JPH08509955A (ja) 1996-10-22
WO1994016741A1 (fr) 1994-08-04
EP0681484A1 (fr) 1995-11-15
AU6128694A (en) 1994-08-15

Similar Documents

Publication Publication Date Title
EP0173629B1 (fr) Complexes d'ions métalliques conjugés avec des anticorps
US4741900A (en) Antibody-metal ion complexes
US5171563A (en) Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
JPH0749377B2 (ja) 機能的特異性抗体
JPH06501703A (ja) 治療用及び診断用撮像組成物及び方法において役立つ錯化剤及びターゲティング放射性免疫試薬
JPH03500419A (ja) 多特異抗白血球結合体及び哺乳動物用非経口的注射剤
JPH10501220A (ja) 放射性核種による放射性免疫検出および放射性免疫療法のためのタンパク質のチオール化
CA2150477A1 (fr) Ciblage sequentiel des sites tumoraux a l'aide de conjugues oligonucleotidiques d'anticorps et de conjugues oligonucleotidiques complementaires de radionucleides chelates
JPH06507918A (ja) ｉｎ　ｖｉｖｏ　結合対プレターゲティング
JP2975676B2 (ja) 架橋抗体とその製法
JP3074160B2 (ja) 悪性腫瘍用画像化剤
EP0675737A1 (fr) Reactifs a reactivite immunologique utilisant la dihydrofolate reductase
CA2157902A1 (fr) Ciblage de tumeurs a l'aide de conjugues d'oligonucleotide l-enantiomeres d'immunoreactifs et de radionucleides chelates
CA2113578A1 (fr) Composes trifonctionnels specifiques de cellules multiresistantes
Mattes Pharmacokinetics of Antibodies and their Radiolabels
WO1994029333A1 (fr) Reactifs immunoreactifs utilisant la monoamine-oxydase
CA2154896A1 (fr) Agents immunoreactifs utilisant des heterodimeres
Li et al. Prelabeling of Chimeric Monoclonal Antibody L6 with 90Yttrium-and 111Indium-1, 4, 7, 10-tetraazacyclododecane-N, N′, N ″, N‴-tetraacetic acid (DOTA) Chelates for Radioimmunodiagnosis and Therapy
EP4230637A1 (fr) Complexes radioactifs d'anticorps anti-her2 et produit radiopharmaceutique
US7713528B1 (en) Method for in vivo delivery of active compounds using reagent conjugate
Frey Preparation, characterization and biological evaluation of cellobiose and dextran carriers of prosthetically labeled iodine-125 for use in radioimmunotherapy of tumors of glial origin
JPH06509102A (ja) 体内造影抗イディオタイプ抗体を用いた組織特異的造影剤
Pollack et al. Hydrazino-type N 2 S 2 chelators

Legal Events

Date Code Title Description
FZDE Dead